BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 34761602)

  • 1. Characterization of the m6A-related lncRNA signature in predicting prognosis and immune response in patients with colon cancer.
    Chen S; Li X; Guo L; Zhang J; Li L; Wang X; Zhu Y; Wang J
    J BUON; 2021; 26(5):1931-1941. PubMed ID: 34761602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients.
    Song W; Ren J; Yuan W; Xiang R; Ge Y; Fu T
    Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
    Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
    BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Interferon Gamma-Related Long Noncoding RNA Signature Predicts Prognosis and Indicates Immune Microenvironment Infiltration in Colon Adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Xie Y
    Front Oncol; 2022; 12():876660. PubMed ID: 35747790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N6-methyladenosine Modification-Related Long Non-Coding RNAs are Potential Biomarkers for Predicting the Prognosis of Patients With Osteosarcoma.
    Yang K; Wang F; Li K; Peng G; Yang H; Xu H; Xiang Y; Sun H
    Technol Cancer Res Treat; 2022; 21():15330338221085354. PubMed ID: 35422168
    [No Abstract]   [Full Text] [Related]  

  • 6. N6-Methylandenosine-Related lncRNA Signature Is a Novel Biomarkers of Prognosis and Immune Response in Colon Adenocarcinoma Patients.
    Zhang P; Liu G; Lu L
    Front Cell Dev Biol; 2021; 9():703629. PubMed ID: 34336856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
    Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
    BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of N6-methyladenosine-related lncRNAs in the tumor immune microenvironment and their prognostic role in pancreatic cancer.
    Liu Y; Wang T; Fang Z; Kong J; Liu J
    J Cancer Res Clin Oncol; 2022 Jul; 148(7):1613-1626. PubMed ID: 35314871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-6 methylation-related lncRNA is potential signature in lung adenocarcinoma and influences tumor microenvironment.
    Zheng J; Zhao Z; Wan J; Guo M; Wang Y; Yang Z; Li Z; Ming L; Qin Z
    J Clin Lab Anal; 2021 Nov; 35(11):e23951. PubMed ID: 34558724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
    Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N6-methyladenosine-related lncRNAs identified as potential biomarkers for predicting the overall survival of Asian gastric cancer patients.
    Xu S; Chen W; Wang Y; Zhang Y; Xia R; Shen J; Gong X; Liang Y; Xu J; Tang H; Zhao T; Zhang Y; Chen T; Wang C
    BMC Cancer; 2022 Jul; 22(1):721. PubMed ID: 35778697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of m6A-Related Signatures in the Tumor Immune Microenvironment and Identification of Clinical Prognostic Regulators in Adrenocortical Carcinoma.
    Jin Y; Wang Z; He D; Zhu Y; Hu X; Gong L; Xiao M; Chen X; Cheng Y; Cao K
    Front Immunol; 2021; 12():637933. PubMed ID: 33746977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening of m6A gene-related lncRNAs in colon adenocarcinoma and construction of a prognostic prediction model.
    Jin LP; Sun YW; Liu T; Tai JD
    Eur Rev Med Pharmacol Sci; 2023 Nov; 27(21):10462-10471. PubMed ID: 37975370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a pyroptosis-related lncRNA risk model for predicting prognosis and immune response in colon adenocarcinoma.
    Tan Y; Lu L; Liang X; Chen Y
    World J Surg Oncol; 2022 Apr; 20(1):118. PubMed ID: 35413978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of a novel N6-methyladenosine (m6A)-related multi- long non-coding RNA (lncRNA) prognostic signature in pancreatic adenocarcinoma.
    Yuan Q; Ren J; Li L; Li S; Xiang K; Shang D
    Bioengineered; 2021 Dec; 12(1):2432-2448. PubMed ID: 34233576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma.
    Liu C; Liu D; Wang F; Liu Y; Xie J; Xie J; Xie Y
    Front Immunol; 2022; 13():1038927. PubMed ID: 36451813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of lncRNA-Associated ceRNA Network Reveals Potential lncRNA Biomarkers in Human Colon Adenocarcinoma.
    Zhang Z; Qian W; Wang S; Ji D; Wang Q; Li J; Peng W; Gu J; Hu T; Ji B; Zhang Y; Wang S; Sun Y
    Cell Physiol Biochem; 2018; 49(5):1778-1791. PubMed ID: 30231249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing a RiskScore Model based on Angiogenesis-related lncRNAs for Colon Adenocarcinoma Prognostic Prediction.
    Li X; Lei J; Shi Y; Peng Z; Gong M; Shu X
    Curr Med Chem; 2024; 31(17):2449-2466. PubMed ID: 37961859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
    Zhao J; Lin X; Zhuang J; He F
    Front Genet; 2021; 12():714697. PubMed ID: 34777460
    [No Abstract]   [Full Text] [Related]  

  • 20. Metabolism-related lncRNAs signature to predict the prognosis of colon adenocarcinoma.
    Sun Y; Liu B; Xiao B; Jiang X; Xiang JJ; Xie J; Hu XM
    Cancer Med; 2023 Mar; 12(5):5994-6008. PubMed ID: 36366731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.